Search tips
Search criteria 


Logo of brjpharmLink to Publisher's site
Br J Pharmacol. 2010 November; 161(5): 961–971.
PMCID: PMC2972645

Structural interpretation of P2X receptor mutagenesis studies on drug action


P2X receptors for ATP are ligand gated cation channels that form from the trimeric assembly of subunits with two transmembrane segments, a large extracellular ligand binding loop, and intracellular amino and carboxy termini. The receptors are expressed throughout the body, involved in functions ranging from blood clotting to inflammation, and may provide important targets for novel therapeutics. Mutagenesis based studies have been used to develop an understanding of the molecular basis of their pharmacology with the aim of developing models of the ligand binding site. A crystal structure for the zebra fish P2X4 receptor in the closed agonist unbound state has been published recently, which provides a major advance in our understanding of the receptors. This review gives an overview of mutagenesis studies that have led to the development of a model of the ATP binding site, as well as identifying residues contributing to allosteric regulation and antagonism. These studies are discussed with reference to the crystal to provide a structural interpretation of the molecular basis of drug action.

Keywords: ATP, P2X, ion channel, structure-function, mutagenesis

Perspective and functional roles of P2X receptors

ATP is more than just an intracellular energy carrier, it is an extracellular transmitter binding to, and activating ligand gated P2X receptors and G-protein coupled P2Y receptors (Burnstock and Kennedy, 1985; Dubyak, 1991; Abbracchio and Burnstock, 1994). P2 purinergic receptors were first proposed in the 1970s by Professor Geoffrey Burnstock (for a historical review, see Burnstock, 2006a), have subsequently been shown to be expressed in almost all cell types, and mediate functions from taste sensation to the recruitment of phagocytes to apoptotic cells (Finger et al., 2005; Elliott et al., 2009). The seven mammalian P2X subunits (P2X1-7) assemble as homomeric and heteromeric receptors with a range of phenotypes (North, 2002; Egan et al., 2004; Roberts et al., 2006). Pharmacological profiling, expression analysis, as well as knockout and knock-down approaches have defined the contributions of P2X receptors in native systems and suggested that P2X receptor selective drugs will be useful in the treatment of a variety of conditions including thromboembolism, bladder instability, pain and inflammation (Roberts et al., 2006; Burnstock, 2006b; Surprenant and North, 2009). The recent publication of a crystal structure of the zebra fish P2X4 (zP2X4) receptor in a closed agonist-unbound state (Kawate et al., 2009) is a major advance for the understanding of P2X receptors. This review focuses on the molecular basis of P2X receptor pharmacological properties and how the crystal structure expands our understanding of the channel.

Pre-crystalization structural insight

P2X receptors were originally identified at the molecular level by expression cloning from the vas deferens and phaeochromocytoma (PC12) cells (Brake et al., 1994; Valera et al., 1994). These receptors had no sequence homology with other ion channels, so bio-informatic and molecular/biochemical studies were first used to develop an understanding of the receptor structure. Sequence and hydrophobicity analysis suggested the P2X receptor subunit had two transmembrane (TM) segments, intracellular amino and carboxy termini and a large extracellular ligand binding loop (Brake et al., 1994; Valera et al., 1994). This topology was supported by immunohistochemical (Vulchanova et al., 1996), mutagenesis (Buell et al., 1996), and glycosylation studies (Newbolt et al., 1998; Torres et al., 1998) (for review, see North, 2002). Like the other families of ligand gated ion channels (LGICs), P2X receptors form as multimers. Evidence for this came initially from studies co-expressing slowly desensitizing α,β-meATP-insensitive P2X2 receptors, and rapidly desensitizing α,β-meATP-sensitive P2X3 receptor subunits. This gave rise to a novel P2X2/3 heteromeric receptor that had the slowly desensitizing time course of the P2X2 receptor and the α,β-meATP sensitivity of the P2X3 receptor subunit (Lewis et al., 1995). The subunit stochiometry was subsequently shown to be a trimer by Nicke et al. (Nicke et al. 1998) based on the size of P2X receptors in Western blot studies using native blue gels or of cross-linked receptors. This agreed well with early predictions that three molecules of ATP were required to activate the channel (Bean, 1990), and also with subsequent models of opening based on single channel analysis (Ding and Sachs, 1999). These studies showed the stoichiometry and topology of P2X receptors was distinct from the pentameric nicotinic/cys loop and the tetrameric glutamate families of ionotropic receptors, which possess four and three membrane spanning segments, respectively, per subunit (Surprenant et al., 1995). P2X receptors are therefore a third structural class of LGIC that form as trimers from subunits with two transmembrane segments, intracellular amino and carboxy termini, and a large extracellular loop.

Prior to a high-resolution crystal structure of the P2X receptor, predictions about tertiary structure came from cysteine mutagenesis studies. There are 10 conserved cysteine residues in the extracellular domain of mammalian P2X receptors that could form disulphide bonds and constrain the receptor structure. Cysteine reactive (2-aminoethyl) methanethiosulfonate hydrobromide-biotin was unable to bind to wild-type P2X1 receptors suggesting that no free cysteine residues were accessible (Ennion and Evans, 2002). However, biotinylation was detected when individual cysteine residues were mutated, as predicted if a cysteine to alanine mutation disrupted a disulphide bond pairing and exposed the free cysteine binding partner (Ennion and Evans, 2002). Single cysteine mutants also changed P2X receptor pharmacological properties, with similar effects for pairs of cysteine mutants (Clyne et al., 2002b; Ennion and Evans, 2002). These findings suggested that disulphide bonds formed between cysteines 1–6, 2–4, 3–5, 7–8 and 9–10 in the extracellular domain (Ennion and Evans, 2002; Clyne et al., 2002b). The disulphide bonding of the first six cysteine residues in the extracellular domain predicted the formation of a finger-like motif. Interestingly, mutation of several residues within this region reduced the allosteric effects of divalent cations and protons on ATP-evoked currents (for review, see Evans, 2009), and mutation of the cysteines abolished regulation by zinc at P2X2 receptors (Clyne et al., 2002b). This suggests that the cysteine-bonded finger forms an allosteric regulatory domain. The co-expression of mutations that introduced additional cysteine residues into the extracellular domain can result in disulphide bond formation between adjacent subunits when the introduced residues are sufficiently close and in the correct orientation. This method provided information on the proximity of residues in adjacent subunits (Jiang et al., 2003) and suggested that the ATP binding and regulatory allosteric sites are formed at the interface between P2X receptor subunits (Nagaya et al., 2005; Marquez-Klaka et al., 2007) (see below for details). Cysteine mutagenesis studies have therefore been useful in providing the first insight into P2X receptor structural constraints and molecular distances between residues.

The first glimpses of the P2X receptor 3D structure came following receptor purification, atomic force microscopy and cryo-EM. These studies support the trimeric assembly of the receptor (Barrera et al., 2005; Mio et al., 2005; Nakazawa et al., 2005; Young et al., 2008). Recently, a structure at 15 Å resolution for the P2X2 receptor has been published (Mio et al., 2009). These structures showed that the receptor has threefold symmetry, a globular extracellular domain, and identified interactions between the intracellular amino and carboxy termini.

Crystalization of the zebra fish P2X4 receptor

The crystallization of membrane proteins is difficult and often requires modifications of the receptor to be made. The zP2X4 receptor took 7 years to solve (Silberberg and Swartz, 2009) requiring truncation, mutation and considerable patience (the ΔP2X4-B mutant alone took 9 months for the crystals to grow (Kawate et al., 2009). This crystal structure confirms the receptor topology, that it is a trimer with threefold symmetry, and also shows that the extracellular domain projects 70 Å above the cell surface. The TM regions are shaped like an hourglass and are similar to those of the two TM segment trimeric acid sensing ion channel (ASIC) (Gonzales et al., 2009). In the extracellular domain, the three P2X receptor subunits are entwined with a right-handed twist (Figure 1A), and there are three vestibules in the centre of the extracellular domain. This crystal structure also confirms the predicted disulphide bonding pattern of the receptor and the existence of a cysteine-rich finger domain. An excellent review of the structural information and comparison with other P2X receptor structures has been published recently (Young, 2009). The zP2X4 receptor was crystallized in the absence of ligand, and no confirmation was given that the purified protein could bind agonists or antagonists. The structure therefore provides no direct information on ATP binding, and this should be borne in mind as a caveat for interpretation. However, a possible agonist binding site was proposed based on previous mutagenesis studies. The remainder of the review summarizes the information available on ligand action and regulation from mutagenesis studies and discusses its interpretation in light of the zP2X4 receptor crystal structure.

Figure 1
Crystal structure of the zebra fish P2X4 (zP2X4) receptor and the proposed sites for agonist and antagoinist binding. (A) Homology model of the human P2X1 receptor based on the structure of the zP2X4 receptor (Kawate et al., 2009) showing the three entwined ...

Mutagenesis based predictions of the ATP binding site

Analysis of a wide range of proteins has identified several consensus motifs for ATP binding. For example, the Walker GXXXXGKT/S motif (X denotes any residue) can coordinate binding of the phosphate of ATP (Walker et al., 1982), and a Q-motif comprising a conserved glutamine and an aromatic amino acid 17 amino acids upstream can contribute to adenine binding (Tanner et al., 2003). However, such consensus motifs for ATP binding are not present in the P2X receptor family. Consequently a mutagenesis-based approach was used to determine the site of agonist action. Alanine is widely used in site directed mutagenesis studies, as this simple amino acid is well tolerated as a substitution. Initial studies focused on determining the effects of alanine mutations of conserved basic, aromatic and polar amino acids in the extracellular domain (Figure 2). The assumption being that as all the P2X receptors are activated by ATP, it is likely that they share a common core ATP binding site.

Figure 2
Conserved amino acids in the extracellular domain of mammalian P2X receptors and the effects of P2X1 receptor mutants on ATP potency. Amino acid sequences of the extracellular domain of human P2X1, 2 and 4 receptors are shown. Residues that are conserved ...

Positively charged amino acids are involved in coordinating the binding of the negatively charged phosphates of ATP. Mutants generated on P2X1 and P2X2 receptor backgrounds showed that residues Lys68, Lys70, Arg292 and Lys309 contribute to ATP potency (P2X1 receptor numbering)(Ennion et al., 2000; Jiang et al., 2000); with the greatest, >1000-fold, decreases in ATP sensitivity for Lys68Ala and Lys309Ala mutants at the P2X1 receptor (Ennion et al., 2000). Aromatic amino acids bind the adenine ring of ATP in DEAD box helicases (Tanner et al., 2003) and the ribose of ATP in UvrB DNA helicase (Theis et al., 1999). Mutagenesis of conserved aromatic amino acids in the P2X1 receptor demonstrated a contribution of Phe185 and Phe291 in agonist action (Roberts and Evans, 2004), with ~10 and 140-fold reduction in ATP potency following alanine replacement mutagenesis respectively. Polar amino acids can also contribute to agonist binding, and mutagenesis studies on P2X1 and P2X2 receptors highlighted a role of Thr186 and Asn290 (P2X1 receptor numbering) in ATP sensitivity (Jiang et al., 2000; Roberts and Evans, 2006).

To date, more than 120 of the ~280 amino acids in the extracellular domain of the human P2X1 receptor, including over 60 conserved residues, have been mutated to alanine and/or cysteine (Evans, 2009; Roberts et al., 2009) (Figure 2). The majority of these mutants had little or no effect on ATP potency; only eight of the mutants made substantial contributions to ATP sensitivity. Based on these studies, a model of how ATP binds to the receptor was proposed (Figure 1C), with lysine residues 68, 70 and 309 coordinating the binding of the negatively charged phosphate tail of ATP. Binding of the adenine ring may be coordinated by the aromatic region Asn290Phe291Arg292, with a regulatory role of Phe185Thr186 possibly by hydrogen bonding (all P2X1 receptor numbering) (Roberts et al., 2006; Roberts et al., 2009). The amino acids proposed in the model are conserved across mammalian P2X receptors, with similar effects of mutations of these residues reported for P2X2 and P2X4 receptors (Jiang et al., 2000; Zemkova et al., 2007; Roberts et al., 2008), suggesting a common core ATP binding pocket.

The predicted ATP binding site is formed from four discrete clusters of amino acids (corresponding to residues 68, 70, 185, 186, 290, 291, 292, and 309 detailed above) that are separated by 115, 104 and 17 residues. This implies that the receptor must be folded/assembled in such a way as to bring these regions close together. The proximity of two of these clusters has been confirmed by cysteine replacement mutagenesis in the P2X1 receptor, which showed cysteine mutants of Lys68 and Phe 291 were sufficiently close to form a disulphide bond. This bond formed between adjacent subunits, and was inhibited in the presence of ATP (Marquez-klaka et al., 2007). These results, in addition to supporting the model, also provide evidence that the ATP binding site forms at the interface between adjacent subunits, as had been suggested from studies on lysine mutants in P2X2/3 receptor heteromers (Wilkinson et al., 2006).

Compatibility of mutagenesis based model for the ATP binding site and structural data

Although the zP2X4 receptor was crystallized in the absence of ATP (Kawate et al., 2009), it does allow mutagenesis studies to be interpreted in a structural context and highlights a region that incorporates several residues important for determining P2X receptor pharmacological properties. The zP2X4 receptor crystal structure shows that the eight conserved residues predicted to contribute to the ATP binding site are indeed in close proximity (Kawate et al., 2009), and this has also been found for a homology model of the P2X1 receptor (Lys68, Lys70, Phe185, Thr 186 from one subunit, and Asn290, Phe291, Arg292 and Lys309 in the adjacent one; P2X1 receptor numbering, Figure 1) and P2X2 receptors (Keceli and Kubo, 2009; Kubo et al., 2009). Further support that this region forms the agonist binding site comes from (i) the substantial effects of mutations of only these residues on ATP potency (Jiang et al., 2000; Zemkova et al., 2007; Roberts et al., 2008) and radioligand binding (Roberts and Evans, 2004; Roberts et al., 2009); (ii) the presence of the only conserved basic residues that are involved in determining agonist sensitivity (Lys 68, 70, 309, and Arg292 P2X1 numbering); it would be extraordinary if the ATP binding pocket did not include positively charged amino acids to coordinate the binding of the negatively charged phosphates; and (iii) residues involved in both allosteric regulation and antagonist action form a halo around this region (Figure 3, see later). These lines of evidence, though compelling, are circumstantial and do not directly prove the location of the ATP binding site. Studies on the P2X7 receptor, however, provide direct evidence to substantiate the location of agonist binding site. ADP-ribosyltransferases transfer ADP-ribose from NAD onto proteins and ADP-ribosylation at Arg125 activates P2X7 receptors (Adriouch et al., 2007). Furthermore, in the zP2X4 receptor structure, the equivalent residue to Arg 125 is adjacent to the predicted ATP binding pocket. This suggests that ADP tethered by ribosylation to Arg125 on the P2X7 receptor can access that adjacent ATP binding pocket and activate the receptor (Adriouch et al., 2007; Schwarz et al., 2009).

Figure 3
Mapping of residues involved in gating and ionic regulation to the P2X receptor structure. An homology model of the hP2X1 receptor built using the zebra fish P2X4 (zP2X4) receptor structure. Left-hand panel shows a surface rendered representation of the ...

If the region predicted to be the ATP binding site is correct, what insight does the zP2X4 receptor structure give to interpretation of mutagenesis studies and development of the model? In the model, it seems most likely that the conserved lysine residues contribute to binding of the phosphate of ATP as cysteine mutants of these residues show that ATP potency can be increased by positively charged MTS reagents and reduced by negatively charged MTS reagents (Roberts and Evans, 2007; Roberts et al., 2008). From the structure of the zP2X4 receptor, it is clear that the conserved lysine residues are not buried within the protein, but are exposed on the surface within the predicted binding groove, raising the possibility that substitutions at the phosphate end of the ATP molecule could easily be accommodated. Support that the region around the terminal phosphate is open at the protein surface and comes from ADP ribosylation (see above)(Adriouch et al., 2007). In addition, the ATP analogues adenosine tetraphosphate and diadenosine pentaphosphate (Ap5A) are agonists at some, but not all P2X receptors, showing that bulky substitutions, such as the addition of an ADP to ATP to make Ap5A, can be accommodated at the P2X1 receptor binding pocket (Ralevic et al., 1995; Lewis et al., 2000). These results suggest that the terminal phosphate of ATP faces out of the binding pocket, and the adenine and ribose components of ATP are bound deeper within the protein or further along the binding groove.

Phenylalanines can form part of a motif for adenine binding (Tanner et al., 2003). Phe291 (P2X1 receptor numbering) was suggested to bind the adenine ring of ATP as mutation decreased agonist potency at P2X1, 2 and 4 receptors (Roberts and Evans, 2004; Roberts et al., 2008). Interestingly, CTP is also a weak agonist at P2X receptors (Chen et al., 1995; Soto et al., 1996; Roberts and Evans, 2004), although whether the pyrimidine ring binds in the same way as adenine remains to be determined. The zP2X4 receptor shows that the conserved phenylalanine predicted to be involved in agonist recognition is the residue in the model that is farthest from the outer surface of the receptor (Kawate et al., 2009). This supports results from mutagenesis studies at P2X2 and P2X4 receptors, where cysteine mutants of these residues were not affected by MTS reagents and were considered inaccessible to these compounds (Roberts et al., 2008). However, at P2X1 receptors, Phe291Cys was inhibited by both positive and negatively charged MTS reagents demonstrating accessibility and suggesting that it contributes to the ATP binding pocket. These differences between P2X receptors suggest that there are subtle variations in geometry between receptor subtypes. At P2X1 receptors, the accessibility of Phe291Cys is consistent with the disulphide bond that can form between Phe291Cys and Lys68Cys in an adjacent subunit (Marquez-Klaka et al., 2007). However, disulphide bond formation for equivalent mutations was less efficient for P2X2 receptors, and a bi-functional cysteine reactive cross-linker was required to form disulphided receptor dimers for P2X3 and P2X4 receptors (Marquez-klaka et al., 2009). Such differences in structure between receptors may be important in determining the subunit dependent pharmacological properties.

The predicted roles for the lysines 68, 70 and 309 in phosphate binding and phenylalanine 291 in binding the adenine ring suggests that Asn290 and Arg292 could be involved coordinating the binding of the ribose of ATP. The original model developed from P2X1 receptor mutagenesis studies also incorporated Phe185 Thr186, since alanine mutants of these residues decreased ATP potency (Roberts and Evans, 2004; Roberts & Evans, 2006). The 10-fold decrease in ATP potency for Phe185 with alanine substitution was modest (Roberts and Evans, 2004), and there was no change in sensitivity for the cysteine mutant (Roberts et al., 2009). In addition for the Phe185Cys mutant ATP potency was not changed by application of cysteine reactive MTS reagents even though they are able to bind to the receptor (Roberts et al., 2009). Similarly, at P2X2 and P2X4 receptors, the equivalent cysteine mutants did not modify ATP sensitivity (Roberts et al., 2008). These results suggest that the conserved residue Phe185 (P2X1 receptor numbering) does not directly interact with ATP at the binding pocket. At the adjacent conserved threonine residue, cysteine mutants had modest effects on ATP potency, and were sensitive to MTS reagents at P2X1, 2 and 4 receptors (Roberts et al., 2008; Roberts et al., 2009). This suggests that the conserved threonine contributes to ATP action. From the zP2X receptor structure, the PheThr doublet is adjacent to a conserved lysine residues, and Thr186 may therefore play a role in fine tuning the interaction of the phosphate tail of ATP with Lys70.

The binding of ATP to the P2X receptor results in conformational changes that lead to the opening of the channel pore (gating of the channel). The zP2X4 receptor structure shows that the proposed ATP binding site is ~45 Å from the channel pore, and it is unclear how agonist binding leads to the conformational changes that underlie opening/gating of the channel. Changes in ATP potency at mutant P2X receptors can arise from an effect on agonist binding and/or gating of the receptor. A radiolabelled 2-azido ATP binding assay was used to give insight into the interpretation of mutagenesis studies (Roberts and Evans, 2007). Binding of 2-azido ATP was reduced for cysteine mutants of Asn290, Phe291, Arg292 and Lys309 at the P2X1 receptor. However, the extent of the reduction did not mirror exactly the changes in ATP potency. Binding was reduced by ~50% for Asn290Cys and Phe291Cys, which showed ~50-fold reduction in ATP potency, while binding was reduced by >80% for Arg292Cys and Lys309Cys, which had 15- and 180-fold reductions in potency respectively (Roberts and Evans, 2007). These discrepancies between the changes in potency and binding can be explained by an effect on gating. The reduced potency at Arg292Cys may have resulted predominantly from an effect on binding (Roberts and Evans, 2007). In contrast, for the cysteine mutants Asn290 and Phe292, an effect on binding and also a reduction in gating seemed likely (Roberts and Evans, 2007). For Lys309Cys, the level of binding was on the limit of detection, and, compared with the smaller potency change of Arg292Cys with equivalent reduction in binding, suggested that a gating effect was also involved (Roberts and Evans, 2007). This was supported by single channel studies suggesting a gating role of the equivalent lysine residue in the P2X2 receptor (Cao et al., 2007). These results indicate that residues within the binding pocket play a central role in transforming agonist binding into opening of the P2X receptor channel.

Interpretation of mutations that have an effect on ATP potency, but do not fit the proposed model for agonist binding

The effects of some conserved amino acid mutations do not fit the proposed ATP binding site model (described above), and can vary markedly between different P2X receptor subunits. At P2X2 receptors, the Lys188Ala, Asp259Ala and Arg304Ala mutations showed >300-fold decreases in ATP potency (Jiang et al., 2000), whereas equivalent mutations at the P2X1 receptor had no effect or a <10-fold decrease (Ennion et al., 2000; Ennion et al., 2001). The P2X4 receptor mutants Lys190Ala and Phe230Ala were essentially insensitive to ATP (Yan et al., 2005), while the equivalent alanine mutants had little or no effect at P2X1 receptors (Ennion et al., 2000; Roberts and Evans, 2004). At the mouse P2X7 receptor, mutation of the conserved Arg206 to Lys resulted in an increase in ATP potency (Schwarz et al., 2009), while the equivalent alanine mutation at the P2X1 receptor R202A had no effect (Ennion et al., 2000). These results highlight the importance of these residues in some subunits. Why then if the residues are conserved do they not show similar effects when mutated across P2X receptor subunits? P2X receptors show a range of properties dependent on the subtype, and these differences result from variations in amino acid sequence between the receptors. This suggests that the subtype dependent effect of a mutation of a conserved amino acid could also arise from an important regulatory role of a non-conserved residue. For example, at the P2X7 receptor, differences in amino acids at residues 127 and 284 contribute to the variation in agonist sensitivity between the rat and mouse isoforms (Young et al., 2006). In addition, amino acid variations are likely to lead to subtle differences in the structures of P2X receptor subunits (as described above for the ability of cysteine mutants to form disulphide bonds in different P2X receptor subunits (Marquez-Klaka et al., 2009), which can contribute to the heterogeneity in properties. Thus structural variations/non-conserved residues are likely to account for the subunit dependent differences in effects of conserved mutations and mediate the heterogeneity in pharmacological properties between receptor subtypes.

But how can these mutants result in a change in ATP sensitivity when they are not part of the proposed ATP binding site? One explanation is that the residues are involved in conformational changes following agonist binding that lead to the opening/gating of the P2X receptor ionic pore. Interestingly, mapping these residues onto the P2X receptor structure shows the majority are located in a ring below the proposed ATP binding pocket (Figure 3). This region provides the link between the ATP binding pocket and the channel pore and changes in properties could affect gating of the channel and ligand sensitivity. As the residues are in different stretches of the protein, it also suggests that interactions between portions are important and the whole region may undergo structural rearrangement following agonist binding and, significant movement in this region may provide the transition to open the channel gate.

Allosteric modulatory sites

The binding of ATP to the P2X receptor orthosteric site can be regulated by a number of allosteric agents, including divalent cations and protons. For example, the sensitivity of ATP at neuronal P2X receptors was increased by low concentrations of zinc (Cloues et al., 1993; Li et al., 1993). Mutagenesis studies have shown that histidine residues His120 and His213 underlie zinc potentiation at rat P2X2 receptors (Clyne et al., 2002a; Lorca et al., 2005). Subsequent elegant studies showed that cysteine mutants of these residues formed an inter-subunit disulphide bond, demonstrating the close proximity of the histidine residues in adjacent subunits (Nagaya et al., 2005). Earlier work suggested that mutation of cysteine residues in the cysteine rich domain (incorporating cysteines 1-6) disrupted zinc regulation, suggesting that disulphide bonds in the cysteine rich finger domain stabilize the zinc binding site (Clyne et al., 2002b; Coddou et al., 2007). The importance of the cysteine rich region has also been shown for regulation by copper (Coddou et al., 2007). It is tempting to speculate that zinc could act to stabilize a conformational change associated with ATP binding and thus increase agonist potency. The P2X2 receptor double mutant His120Cys/His213Cys showed barely detectable responses to ATP; however, on treatment with the reducing agent, DTT currents were increased (Nagaya et al., 2005). This suggests that the disulphide bond between the introduced cysteines either restricted access of ATP to the binding site or a conformational change associated with binding, and/or gating. Interestingly, His120 in the P2X2 receptor is equivalent to Arg125 in the P2X7 receptor, which is ADP ribosylated and can lead to receptor activation (Adriouch et al., 2007), once again highlighting that this residue is close to the ATP binding site. The zP2X4 receptor crystal structure confirms these predictions, and shows that the residues are in close proximity to the predicted ATP binding site (Figure 1).

Trivalent cations can also have a regulatory role inhibiting P2X receptor function (Nakazawa et al., 1997). Lanthanum and gadolinium blocked P2X1 and P2X2 currents in oocytes; this inhibition appeared competitive and was reversed by increasing the ATP concentration (Nakazawa et al., 1997). The crystal of the zP2X4 receptor was solved in the presence of gadolinium, with residues Asp184 and Asn187 on the upper outer region of the receptor, and Glu98 at the core vestibule, coordinating the binding of the trivalent ion (Kawate et al., 2009). Asn187 is just adjacent to Phe188Thr189, which are thought to contribute to the ATP binding pocket, suggesting that gadolinium binding at Asp 184 and Asn187 reduces ATP affinity. Interestingly, gadolinium increases recovery from desensitisation at transient sensory P2X and rat P2X3 receptors (Cook et al., 1998). At these receptors, recovery from desensitisation and agonist unbinding were strongly linked (Pratt et al., 2005). This indicates that gadolinium speeds the unbinding of agonist from P2X3 receptors and is consistent with an effect on reducing ATP affinity. These results suggest that the high (1 mM) gadolinium used in the receptor crystallization may make it difficult to solve the structure in an ATP bound form.

Protons can also regulate P2X receptors with the effect dependent on the channel subtype (Stoop et al., 1997). Histidine residues mediate proton sensitivity at P2X2, 3, 4 and 7 receptors, although different residues are involved in each of these subunits. At P2X2 receptors, the His319Ala mutation reduced the potentiating effects of protons on ATP sensitivity (Clyne et al., 2002a), while mimicking protonation of His319 with the His319Lys mutation increased ATP potency 40-fold. Analysis of the structure for the zP2X4 receptor predicts that His319 lines the vestibule formed at the centre of the receptor (Figure 3) and could therefore contribute to channel gating. In contrast, at P2X3 receptors, protons decrease ATP responses (Stoop et al., 1997), and His206 contributes to proton sensitivity, as well as recovery from desensitisation (Gerevich et al., 2007). P2X4 receptors were also inhibited by protons, and His286 mediates this effect (Clarke et al., 2000). Interestingly, although different histidine residues are involved in proton inhibition at P2X3 and P2X4 receptors, the residues are predicted to be on the surface of the receptor (Figure 3) in the ring below the predicted ATP binding site, where mutants may have an effect on ATP potency. This raises the possibility that protonation of the histidine reduces gating and thus potency (see above). At P2X7 receptors, His130 was involved in proton sensitivity (Acuna-castillo et al., 2007), and this residue forms part of the cysteine rich region (Figure 3) that also contributes to divalent cation sensitivity.

Antagonist binding sites

P2X receptor antagonists have been suggested to have therapeutic potential in several diseases (Burnstock, 2006b) and a range of subtype selective compounds have been described, for example P2X1 receptor selective NF449 (Braun et al., 2001) and P2X3 receptor selective A317491 (Jarvis et al., 2002). However, our understanding of the molecular basis of antagonist action is limited and focused on the relatively non-selective antagonists pyridoxal 5-phosphate 6-azophenyl-2′,4′-disulphonic acid (PPADS) and suramin (North and Surprenant, 2000).

PPADS acts non-competitively, and at high concentrations depresses maximal responses to ATP. The rat P2X4 (rP2X4) receptor is insensitive to commonly used antagonists (Buell et al., 1996). PPADS can form a Schiff based with lysine residues, and a lysine present in PPADS sensitive P2X1 and P2X2 receptors is replaced by a glutamic acid residue in the rP2X4 receptor. Mutation of this glutamic acid residue at position 249 in the rP2X4 receptor to lysine recovered sensitivity to PPADS (Buell et al., 1996). However, the reverse mutation in the P2X2 receptor (Lys246Glu) did not remove PPADS inhibition. Furthermore, this lysine residue is not present in PPADS-sensitive human P2X3 and P2X7 receptors, and therefore other residues are also likely to contribute to the antagonist binding site (Buell et al., 1996). Subsequent cloning of the human and mouse P2X4 receptors showed that they were more sensitive to PPADS than the rat form (Garcia-Guzman et al., 1997b; Jones et al., 2000); however, they showed essentially identical amino acid sequence around residue 249, suggesting that another region of the receptor was also involved in determining PPADS sensitivity. A chimeric approach was used to determine what was responsible for the PPADS sensitivity differences between human and rat P2X4 receptors, which showed residues in the region 81–183 also contribute to PPADS sensitivity (Garcia-Guzman et al., 1997a). Species differences in PPADS sensitivity at P2X7 receptors were also utilized to generate chimeras and point mutations that identified a contribution of Arg126 to PPADS action (Michel et al., 2008). The mutated residues shown to have an effect on PPADS sensitivity are positively charged, which fits with a role in coordination of the negative charge of the antagonists PPADS. Mapping these residues (equivalent to Arg 249 from the P2X4 and 126 from the P2X7 receptor) onto a homology model structure of the P2X1 receptor shows that they are located either side of the proposed agonist binding site (Figure 1B–D). Binding of PPADS at either of these sites could therefore restrict access of ATP to its binding site and account for its antagonistic effect.

Suramin appears to be a competitive antagonist, and insight into its binding site has come from differences in properties between species variants of P2X receptor subunits. For the P2X4 receptor, point mutation showed residue 78 was associated with differences between rat and human receptors; for the mutant rat P2X4 Gln78Lys, the sensitivity was increased ~10-fold (Garcia-Guzman et al., 1997a). However, this was still >100-fold lower than suramin affinity at the hP2X1 receptor (Roberts and Evans, 2004), suggesting that additional residues also contribute substantially to sensitivity. The marked differences in sensitivity of human and mouse P2X1 receptors to suramin have also been used to identify Lys138 as contributing to the antagonist action of suramin and its derivative NF449 that is effective at low nanomolar concentrations (Braun et al., 2001; Sim et al., 2008). However, this residue is not conserved among suramin sensitive receptors, and it has been suggested that it is the localized positive charge that is important in modulating the actions of the negatively charged suramin (Braun et al., 2001; Sim et al., 2008).

Suramin can act as a partial agonist at constitutively active P2X2 receptors (Cao et al., 2007), and radioligand binding studies have shown that suramin can competitively displace radioligands from P2X receptors (Michel et al., 1996). This raises the possibility that the same residues may be involved in suramin and ATP binding. However, alanine mutants of the conserved positively charged Lys, Arg and Phe residues in the P2X1 receptor, which reduced ATP potency by >100-fold, had little (Arg292Ala) or no effect (Lys68Ala, Lys70Ala and Lys309Ala) (Ennion et al., 2000) or actually increased (Phe291Ala) (Roberts and Evans, 2004) suramin sensitivity. This shows that key residues involved in ATP potency do not have an effect on suramin sensitivity, and indicate there is not significant overlap in the particular residues involved in suramin and ATP binding. The homology model of the hP2X1 receptor also suggests that the mutants that can change suramin sensitivity do not appear to interact directly with residues that form the proposed ATP binding site. The Lys138 side chain, shown to regulate suramin sensitivity at the P2X1 receptor (Sim et al., 2008), does not line the ATP binding pocket, but faces away from it and is on the other side of the cysteine rich region (Figure 1). The proximity to, but not direct interaction with the proposed ATP binding site, suggests that suramin may act by stabilizing particular conformational states of the receptor or its binding occludes subsequent ATP binding and either of these mechanisms could account for the competitive antagonism.

Suramin and PPADS are effective antagonists at most, but not all P2X receptors. Therefore, it is likely that each antagonist may share key core conserved residues involved in binding across subunits in addition to those residues described above that can regulate sensitivity. However, whether this is the case, or there is a more variable/diffuse binding site of non-conserved residues in a general area remains to be determined. The zP2X4 receptor structure has given an insight into where antagonists may act and highlights adjacent regions of interest for future mutagenesis studies.

Transmembrane regions

Cysteine scanning mutagenesis studies showed that both TMs could contribute to the permeation properties of P2X receptors (Rassendren et al., 1997; Egan et al., 1998; Jiang et al., 2001; Haines et al., 2001b; Li et al., 2008). Determination of the rates of modification of introduced cysteine residues suggested that TM2 lined the pore and contained the channel gate, and that TM1 was peripheral to the pore region (Li et al., 2008). These predictions are supported by the zP2X4 receptor structure (Kawate et al., 2009), and, interestingly, the arrangement of the TMs is essentially the same as trimeric two TM ASIC channels (Gonzales et al., 2009). While it is clear that the TM2 region forms the ionic permeation pathway, TM1 also contributes to control of the gating of the channel as shown by a chimera of TM1 of P2X1 added to P2X2 increasing sensitivity to α,β-methylene ATP (Haines et al., 2001a), and the converse chimera with TM1 of P2X2 changing P2X1 from a desensitizing to non-desensitizing phenotype (Rettinger and Schmalzing, 2004). Elegant single-channel analysis of TM2 mutants have demonstrated residues that play a role in the gating, single-channel conductance and rectification of the P2X2 receptor and have given an important insight into the gate and channel opening of P2X receptors (Cao et al., 2007; Cao et al., 2009). Studies on the P2X receptor TM domains have clearly shown that they both play a role in determining ATP responsiveness, and it is clear that TM derived differences in gating between the receptors could contribute to the variation in agonist sensitivity.

Future directions

The structure of the zP2X4 receptor has provided a major advance in our understanding of P2X receptors, insight into the interpretation of mutagenesis studies and a model of where ATP binds to the receptor. This review provides an overview of mutagenesis studies on several P2X receptor subunits that supports a conserved consensus core ATP binding pocket at P2X receptors, with the negative charge of the phosphate groups coordinated by conserved Lys residues, and an AsnPheArg motif the may regulate binding of the adenine ring. The differences in ligand sensitivity between subunits (for review, see North and Surprenant, 2000), however, demonstrate clearly that variant amino acids also contribute to, and regulate, pharmacological properties. The variation could arise from single amino acid changes to disrupt gating and/or interaction with the ligand, and/or involve more complex structural changes as suggested by the variation in the distance between introduced cysteine residues in different subunits (Marquez-klaka et al., 2009). A range of studies, including the use of differences in properties between species orthologues, chimaeric receptors and mutations, have identified residues that contribute to the heterogeneity of receptor properties. However, to date, no clear picture has begun to emerge on what underlies the variations in pharmacology, for example the differences in ATP potency, why α,β-meATP is effective at P2X1 and P2X3 but not other P2X receptor subunits, or the mechanism of action of selective antagonists. Additional P2X receptor structures would provide another leap forward in our understanding of this family of receptors and give an insight into subtype dependent differences. Of particular interest would be structures with agonist or antagonist bound to develop models of drug action, aid in the understanding of the subtype dependent basis of pharmacological properties, and gain insight into structural changes in the receptor on activation. However, in their absence, there are a number of areas that can be addressed. (i) Structural-based modelling of drug action: Now that a structure for the zP2X4 receptor is available, molecular-docking programmes can be used to develop models of how ligand binding to the receptor. These models could also be developed to understand the structural basis for differences in pharmacology between subunits and in rational drug design. (ii) Conformational changes: The structure of zP2X4 is in the closed conformation in the absence of ATP and provides a snapshot of one of the conformations that the receptor can adopt. A major question is how ATP binding leads to gating of the channel pore? Techniques to look at changes in accessibility of regions of the protein will be useful, and voltage clamp fluorometry could be used to give some temporal resolution to conformational changes (Pless and Lynch, 2009). (iii) Intracellular domains: Mutations in the intracellular domains can have profound effects on the properties of P2X receptors, and how these are transmitted to the rest of the channel remains to be determined. The association of P2X receptors with interacting proteins (e.g. Kim et al., 2001) provides an added layer of complexity to understand the molecular basis of how the intracellular domains regulate channel function.


This work was supported by the Wellcome Trust. Thanks to Dr A. Gingras for help with PyMOL, Ms Olivia Presley and Dr R. Schmid for work on the hP2X1 receptor homology model, and Dr B.D. Grubb and Professors M.P. Mahaut Smith and I.D. Forsythe for helpful comments.



diadenosine pentaphosphate
acid sensing ion channel
rat P2X4
zebra fish P2X4

Conflict of interest

There is no conflict of interest for the paper.


  • Abbracchio MP, Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmac Ther. 1994;64:445–475. [PubMed]
  • Acuna-Castillo C, Coddou C, Bull P, Brito J, Huidobro-Toro JP. Differential role of extracellular histidines in copper, zinc, magnesium and proton modulation of the P2X7 purinergic receptor. J Neurochem. 2007;101:17–26. [PubMed]
  • Adriouch S, Bannas P, Schwarz N, Fliegert R, Guse AH, Seman M, et al. ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site. FASEB J. 2007;22:861–869. [PubMed]
  • Barrera NP, Ormond SJ, Henderson RM, Murrell-Lagnado RD, Edwardson JM. AFM imaging demonstrates that P2X2 receptors are trimers, but that P2X6 receptor subunits do not oligomerize. J Biol Chem. 2005;280:10759–10765. [PubMed]
  • Bean BP. ATP-activated channels in rat and bullfrog sensory neurons: concentration dependence and kinetics. J Neurosci. 1990;10:1–10. [PubMed]
  • Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature. 1994;371:519–523. [PubMed]
  • Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, et al. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2001;364:285–290. [PubMed]
  • Buell G, Lewis C, Collo G, North RA, Surprenant A. An antagonist-insensitive P2X receptor expressed in epithlia and brain. EMBO J. 1996;15:55–62. [PubMed]
  • Burnstock G. Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci. 2006a;27:166–176. [PubMed]
  • Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev. 2006b;58:58–86. [PubMed]
  • Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol. 1985;16:433–440. [PubMed]
  • Cao L, Broomhead HE, Young MT, North RA. Polar residues in the second transmembrane domain of the rat P2X2 receptor that affect spontaneous gating, unitary conductance, and rectification. J Neurosci. 2009;29:14257–14264. [PMC free article] [PubMed]
  • Cao L, Young MT, Broomhead HE, Fountain SJ, North RA. Thr339-to-serine substitution in rat P2X2 receptor second transmembrane domain causes constitutive opening and indicates a gating role for Lys308. J Neurosci. 2007;27:12916–12923. [PubMed]
  • Chen C-C, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X purincoeptor expressed by a subset of sensory neurons. Nature. 1995;377:428–431. [PubMed]
  • Clarke CE, Benham CD, Bridges A, George AR, Meadows HJ. Mutation of histidine 286 of the human P2X4 purinoceptor removes extracellular pH sensitivity. J Physiol. 2000;523:697–703. [PubMed]
  • Cloues R, Jones S, Brown DA. Zn2+ potentiates ATP-activated currents in rat sympathetic neurons. Pflugers Arch. 1993;424:152–158. [PubMed]
  • Clyne JD, LaPointe LD, Hume RI. The role of histidine residues in modulation of the rat P2X(2) purinoceptor by zinc and pH. J Physiol. 2002a;539:347–359. [PubMed]
  • Clyne JD, Wang LF, Hume RI. Mutational analysis of the conserved cysteines of the rat P2X2 purinoceptor. J Neurosci. 2002b;22:3873–3880. [PubMed]
  • Coddou C, Acuna-Castillo C, Bull P, Huidobro-Toro JP. Dissecting the facilitator and inhibitor allosteric metal sites of the P2X4 receptor channel: critical roles of Cys-132 for zinc-potentiation and Asp-138 for copper-inhibition. J Biol Chem. 2007;282:36879–36886. [PubMed]
  • Cook SP, Rodland KD, McCleskey EW. A memory for extracellular Ca2+ by speeding recovery of P2X receptors from desensitisation. J Neurosci. 1998;18:9238–9244. [PubMed]
  • Ding S, Sachs F. Single channel properties of P2X2 purinoceptors. J Gen Physiol. 1999;113:695–720. [PMC free article] [PubMed]
  • Dubyak GR. Signal transduction by P2-purinergic receptors for extracellular ATP. Am J Respir Cell Mol Biol. 1991;4:295–300. [PubMed]
  • Egan TM, Cox JA, Voigt MM. Molecular structure of P2X receptors. Curr Top Med Chem. 2004;4:821–829. [PubMed]
  • Egan TM, Haines WR, Voigt MM. A domain contributing to the ion channel of ATP-gated P2X2 receptors identified by the substituted cycteine accessibitlity method. J Neurosci. 1998;18:2350–2359. [PubMed]
  • Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature. 2009;461:282–286. [PMC free article] [PubMed]
  • Ennion SJ, Evans RJ. Conserved cysteine residues in the extracellular loop of the human P2X(1) receptor form disulfide bonds and are involved in receptor trafficking to the cell surface. Mol Pharmacol. 2002;61:303–311. [PubMed]
  • Ennion S, Hagan S, Evans RJ. The role of positively charged amino acids in ATP recognition by human P2X1 receptors. J Biol Chem. 2000;275:29361–29367. [PubMed]
  • Ennion SJ, Ritson J, Evans RJ. Conserved negatively charged residues are not required for ATP action at P2X(1) receptors. Biochem Biophys Res Commun. 2001;289:700–704. [PubMed]
  • Evans RJ. Orthosteric and allosteric binding sites of P2X receptors. Eur Biophys J. 2009;38:319–327. [PubMed]
  • Finger TE, Danilova V, Barrows J, Bartel DL, Vigers AJ, Stone L, et al. ATP signaling is crucial for communication from taste buds to gustatory nerves. Science. 2005;310:1495–1499. [PubMed]
  • Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund P-E, Stuhmer W. Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol Pharmacol. 1997a;51:109–118. [PubMed]
  • Garcia-Guzman M, Soto F, Gomez-Hernandez JM, Lund P-E, Stuhmer W. Characterization of recombinant human P2X4 receptor reveals pharmacological differences with the rat homologue. Mol Pharmacol. 1997b;51:109–118. [PubMed]
  • Gerevich Z, Zadori ZS, Koles L, Kopp L, Milius D, Wirkner K, et al. Dual effect of acid pH on purinergic P2X3 receptors depends on the histidine-206 residue. J Biol Chem. 2007;282:33949–33957. [PubMed]
  • Gonzales EB, Kawate T, Gouaux E. Pore architecture and ion sites in acid-sensing ion channels and P2X receptors. Nature. 2009;460:599–604. [PMC free article] [PubMed]
  • Haines WR, Migita K, Cox JA, Egan TM, Voigt MM. The first transmembrane domain of the P2X receptor subunit participates in the agonist-induced gating of the channel. J Biol Chem. 2001a;276:32793–32798. [PubMed]
  • Haines WR, Voigt MM, Migita K, Torres GE, Egan TE. On the contribution of the first transmembrane domain to whole-cell current through an ATP-gated ionotropic P2X receptor. J Neurosci. 2001b;21:5885–5892. [PubMed]
  • Jarvis MF, Burgard EC, McGaraughty S, Honore P, Lynch K, Brennan TJ, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A. 2002;99:17179–17184. [PubMed]
  • Jiang LH, Kim M, Spelta V, Bo X, Surprenant A, North RA. Subunit arrangement in P2X receptors. J Neurosci. 2003;23:8903–8910. [PubMed]
  • Jiang L-H, Rassendren F, Spelta V, Surprenant A, North RA. Amino acid residues involved in gating identified in the first membrane-spanning domain of the rat p2X2 receptor. J Biol Chem. 2001;276:14902–14908. [PubMed]
  • Jiang L-H, Rassendren F, Surprenant A, North RA. Identification of amino acid residues contributing to the ATP binding site of a purinergic P2X receptor. J Biol Chem. 2000;275:34190–34196. [PubMed]
  • Jones CA, Chessell IP, Simon J, Barnard EA, Miller KJ, Michel AD, et al. Functional characterization of the P2X4 receptor orthologues. Br J Pharmacol. 2000;129:388–394. [PMC free article] [PubMed]
  • Kawate T, Michel JC, Birdsong WT, Gouaux E. Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature. 2009;460:592–598. [PMC free article] [PubMed]
  • Keceli B, Kubo Y. Functional and structural identification of amino acid residues of the P2X2 receptor channel critical for the voltage- and [ATP]-dependent gating. J Physiol. 2009;587:5801–5818. [PubMed]
  • Kim M, Jiang L-H, Wilson HL, North RA, Surprenant A. Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J. 2001;20:6347–6358. [PubMed]
  • Kubo Y, Fujiwara Y, Keceli B, Nakajo K. Dynamic aspects of functional regulation of the ATP receptor channel P2X(2) J Physiol. 2009;587:5317–5324. [PubMed]
  • Lewis CJ, Gitterman DP, Schluter H, Evans RJ. Effects of diadenosine polyphosphates (ApnAs) and adenosine polyphospho guanosines (ApnGs) on rat mesenteric artery P2X receptor ion channels. Br J Pharmacol. 2000;129:124–130. [PMC free article] [PubMed]
  • Lewis C, Neidhart S, Holy C, North RA, Buell G, Surprenant A. Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature. 1995;377:432–435. [PubMed]
  • Li M, Chang TH, Silberberg SD, Swartz KJ. Gating the pore of P2X receptor channels. Nat Neurosci. 2008;11:883–887. [PMC free article] [PubMed]
  • Li C, Peoples RW, Li Z, Weight FF. Zn2+ potentiates excitatory action of ATP on mammalian neurons. Proc Natl Acad Sci U S A. 1993;90:8264–8267. [PubMed]
  • Lorca RA, Coddou C, Gazitua MC, Bull P, Arredondo C, Huidobro-Toro JP. Extracellular histidine residues identify common structural determinants in the copper/zinc P2X2 receptor modulation. J Neurochem. 2005;95:499–512. [PubMed]
  • Marquez-Klaka B, Rettinger J, Bhargava Y, Eisele T, Nicke A. Identification of an intersubunit cross-link between substituted cysteine residues located in the putative ATP binding site of the P2X1 receptor. J Neurosci. 2007;27:1456–1466. [PubMed]
  • Marquez-Klaka B, Rettinger J, Nicke A. Inter-subunit disulfide cross-linking in homomeric and heteromeric P2X receptors. Eur Biophys J. 2009;38:329–338. [PubMed]
  • Michel AD, Clay WC, Ng SW, Roman S, Thompson K, Condreay JP, et al. Identification of regions of the P2X(7) receptor that contribute to human and rat species differences in antagonist effects. Br J Pharmacol. 2008;155:738–751. [PMC free article] [PubMed]
  • Michel AD, Lundstrom K, Buell GN, Surprenant A, Valera S, Humphrey PPA. A comparison of the binding characteristics of recombinant P2X1 and P2X2 receptors. Br J Pharmacol. 1996;118:1806–1812. [PMC free article] [PubMed]
  • Mio K, Kubo Y, Ogura T, Yamamoto T, Sato C. Visualization of the trimeric P2X(2) receptor with a crown-capped extracellular domain. Biochem Biophys Res Commun. 2005;337:998–1005. [PubMed]
  • Mio K, Ogura T, Yamamoto T, Hiroaki Y, Fujiyoshi Y, Kubo Y, et al. Reconstruction of the P2X(2) receptor reveals a vase-shaped structure with lateral tunnels above the membrane. Structure. 2009;17:266–275. [PubMed]
  • Nagaya N, Tittle RK, Saar N, Dellal SS, Hume RI. An intersubunit Zn2+ binding site in rat P2X2 receptors. J Biol Chem. 2005;280:25982–25993. [PMC free article] [PubMed]
  • Nakazawa K, Liu M, Inoue K, Ohno Y. Potent inhibition by trivalent cations of ATP-gated channels. Eur J Pharmacol. 1997;325:237–243. [PubMed]
  • Nakazawa K, Yamakoshi Y, Tsuchiya T, Ohno Y. Purification and aqueous phase atomic force microscopic observation of recombinant P2X2 receptor. Eur J Pharmacol. 2005;518:107–110. [PubMed]
  • Newbolt A, Stoop R, Virginio C, Surprenant A, North RA, Buell G, et al. Membrane topology of an ATP-gated ion channel (P2X receptor) J Biol Chem. 1998;273:15177–15182. [PubMed]
  • Nicke A, Baumert H, Rettinger J, Eichele A, Lambrecht G, Mutschler E, et al. P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J. 1998;17:3016–3028. [PubMed]
  • North RA. Molecular physiology of P2X receptors. Physiol Rev. 2002;82:1013–1067. [PubMed]
  • North RA, Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol. 2000;40:563–580. [PubMed]
  • Pless SA, Lynch JW. Ligand-specific conformational changes in the alpha1 glycine receptor ligand-binding domain. J Biol Chem. 2009;284:15847–15856. [PMC free article] [PubMed]
  • Pratt EB, Brink TS, Bergson P, Voigt MM, Cook SP. Use-dependent inhibition of P2X3 receptors by nanomolar agonist. J Neurosci. 2005;25:7359–7365. [PubMed]
  • Ralevic V, Hoyle CHV, Burnstock G. Pivotal role of phosphate chain length in vasoconstrictor versus vasodilator actions of adenine dinucleotides in rat mesenteric arteries. J Physiol. 1995;483:703–713. [PubMed]
  • Rassendren F, Buell G, Newbolt A, North RA, Surprenant A. Identification of amino acid residues contributing to the pore of a P2X receptor. EMBO J. 1997;16:3446–3454. [PubMed]
  • Rettinger J, Schmalzing G. Desensitization masks nanomolar potency of ATP for the P2X1 receptor. J Biol Chem. 2004;279:6426–6433. [PubMed]
  • Roberts JA, Digby HR, Kara M, Ajouz SE, Sutcliffe MJ, Evans RJ. Cysteine substitution mutagenesis and the effects of methanethiosulfonate reagents at P2X2 and P2X4 receptors support a core common mode of ATP action at P2X receptors. J Biol Chem. 2008;283:20126–20136. [PMC free article] [PubMed]
  • Roberts JA, Evans RJ. ATP binding at human P2X1 receptors: contribution of aromatic and basic amino acids revealed using mutagenesis and partial agonists. J Biol Chem. 2004;279:9043–9055. [PubMed]
  • Roberts JA, Evans RJ. Contribution of conserved polar glutamine, asparagine and threonine residues and glycosylation to agonist action at human P2X1 receptors for ATP. J Neurochem. 2006;96:843–852. [PubMed]
  • Roberts JA, Evans RJ. Cysteine substitution mutants give structural insight and identify ATP binding and activation sites at P2X receptors. J Neurosci. 2007;27:4072–4082. [PMC free article] [PubMed]
  • Roberts JA, Valente M, Allsopp RC, Watt D, Evans RJ. Contributions of the region Glu181 to Val200 of the extracellular loop of the human P2X1 receptor to agonist binding and gating revealed using cysteine scanning mutagenesis. J Neurochem. 2009;109:1042–1052. [PMC free article] [PubMed]
  • Roberts JA, Vial C, Digby HR, Agboh KC, Wen H, Atterbury-Thomas AE, et al. Molecular properties of P2X receptors. Pflugers Arch. 2006;452:486–500. [PubMed]
  • Schwarz N, Fliegert R, Adriouch S, Seman M, Guse AH, Haag F, et al. Activation of the P2X7 ion channel by soluble and covalently bound ligands. Purinergic Signal. 2009;5:139–149. [PMC free article] [PubMed]
  • Silberberg SD, Swartz KJ. Structural biology: trimeric ion-channel design. Nature. 2009;460:580–581. [PubMed]
  • Sim JA, Broomhead HE, North RA. Ectodomain lysines and suramin block of P2X1 receptors. J Biol Chem. 2008;283:29841–29846. [PMC free article] [PubMed]
  • Soto F, Garcia-Guzman M, Gomez-Hernandez JM, Hollmann M, Karschin C, Stuhmer W. P2X4: an ATP-activated ionotropic receptor cloned from rat brain. Proc Natl Acad Sci U S A. 1996;93:3684–3688. [PubMed]
  • Stoop R, Surprenant A, North RA. Different sensitivities to pH of ATP-indiced currents at four cloned P2X receptors. J Neurophysiol. 1997;78:1837–1840. [PubMed]
  • Surprenant A, Buell G, North RA. P2X receptors bring new structure to ligand-gated ion channels. TINS. 1995;18:224–229. [PubMed]
  • Surprenant A, North RA. Signaling at purinergic P2X receptors. Annu Rev Physiol. 2009;71:333–359. [PubMed]
  • Tanner NK, Cordin O, Banroques J, Doere M, Linder P. The Q motif: a newly identified motif in DEAD box helicases may regulate ATP binding and hydrolysis. Mol Cell. 2003;11:127–138. [PubMed]
  • Theis K, Chen PJ, Skorvaga M, Van Houten B, Kisker C. Crystal structure of UvrB, a DNA helicase adapted for nucleotide excision repair. EMBO J. 1999;18:6899–6907. [PubMed]
  • Torres GE, Egan TE, Voigt MM. N-linked glycosylation is essential for the functional expression of the recombinant P2X2 receptor. Biochemistry. 1998;37:14845–14851. [PubMed]
  • Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant A, et al. A new class of ligand-gated ion channel defined by P2X receptor for extraxcellular ATP. Nature. 1994;371:516–519. [PubMed]
  • Vulchanova L, Arvidsson U, Riedl M, Buell G, Surprenant A, North RA, et al. Differential distribution of two ATP-gated ion channels (P2X receptors) determined by immunohistochemistry. Proc Natl Acad Sci U S A. 1996;93:8063–8067. [PubMed]
  • Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the alpha- and beta-subunits of ATP synthase, myosin, kinases and other ATP requiring enzymes and a common nucleotide binding fold. EMBO J. 1982;1:945–951. [PubMed]
  • Wilkinson WJ, Jiang LH, Surprenant A, North RA. Role of ectodomain lysines in the subunits of the heteromeric P2X2/3 receptor. Mol Pharmacol. 2006;70:1159–1163. [PubMed]
  • Yan Z, Liang Z, Tomic M, Obsil T, Stojilkovic SS. Molecular determinants of the agonist binding domain of a P2X receptor channel. Mol Pharmacol. 2005;67:1078–1088. [PubMed]
  • Young MT. P2X receptors: dawn of the post-structure era. Trends Biochem Sci. 2009;35:83–90. [PMC free article] [PubMed]
  • Young MT, Fisher JA, Fountain SJ, Ford RC, North RA, Khakh BS. Molecular shape, architecture, and size of P2X4 receptors determined using fluorescence resonance energy transfer and electron microscopy. J Biol Chem. 2008;283:26241–26251. [PMC free article] [PubMed]
  • Young MT, Pelegrin P, Surprenant A. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Mol Pharmacol. 2006;71:92–100. [PubMed]
  • Zemkova H, Yan Z, Liang Z, Jelinkova I, Tomic M, Stojilkovic SS. Role of aromatic and charged ectodomain residues in the P2X(4) receptor functions. J Neurochem. 2007;102:1139–1150. [PubMed]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society